Maze Therapeutics, Inc.
NASDAQMAZE short interest surges 26.5% in one week to 9.1% of float, signaling mounting bearish positioning ahead of earnings Thursday.
Snapshot as of 24 Jun 2026
Maze Therapeutics reports Q1 2026 results on May 14 with short sellers freshly emboldened — and analysts split on how far the MZE829 story can run. The most striking pre-print development is in short positioning. Short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MAZE — free to start on ORTEX.
Sign up for free →Open MAZE on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live MAZE data →